IPA Leadership

Shuji Sato serves as the Vice President of Innovative Solutions for IPA with a focus on consistently delivering high value, technologically advanced scientific services to meet the objectives of the most challenging projects. He has over 20 years of experience in various R&D settings, including directing in vivo and in vitro antibody discovery and development teams at numerous biotech and pharma as well as in academia. He applies his broad knowledge in drug development to conceptualization and realization of projects and drives development of effective and innovative workflows.  

Dr. Sato holds a PhD in Molecular Microbiology from Tufts University and trained as a postdoctoral fellow at Harvard Medical School, prior to joining Cell Signaling Technology’s innovative research group and has held Principal Scientist and Associate Director positions at Bluefin Biomedicine, Pfizer and Dragonfly Therapeutics. Throughout his research career, Dr. Sato has co-authored numerous peer-reviewed scientific articles and patents.